| Overview |
| bs-12918R-PE-Cy5.5 |
| C-REL (Ser503) Polyclonal Antibody, PE-Cy5.5 Conjugated |
| WB |
| Human |
| Specifications |
| PE-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human C-REL around the phosphorylation site of Ser503 |
| Ser503 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5966 |
| Q04864 |
| Nucleus |
| c-Rel phospho S503; c-Rel phospho Ser503; p-c-Rel phospho S503; p-c-Rel S503; Avian reticuloendotheliosis; C REL; C Rel protein; c Rel proto oncogene protein; Oncogene REL; Oncogene REL avian reticuloendotheliosis; REL; v rel avian reticuloendotheliosis viral oncogene homolog; v rel reticuloendotheliosis viral oncogene homolog. |
| The REL gene encodes c-Rel, a transcription factor that is a member of the Rel/NFKB family, which also includes RELA (MIM 164014), RELB (604758), NFKB1 (MIM 164011), and NFKB2 (MIM 164012). These proteins are related through a highly conserved N-terminal region termed the 'Rel domain,' which is responsible for DNA binding, dimerization, nuclear localization, and binding to the NFKB inhibitor (MIM 164008) (Belguise and Sonenshein, 2007 [PubMed 18037997]).[supplied by OMIM, May 2008]. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz